

Supplementary Table S1. Characteristics of AMA users versus non-users in BLISS-52 and BLISS-76.

Study	BLISS-52			BLISS-76			
	AMA	Users	Non-Users	<i>p</i> Value	Users	Non-Users	<i>p</i> Value
Number of patients		579	286		519	300	
		Demographics					
Age (years)		34.9 (11.0)	36.8 (11.1)	0.009	39.0 (11.4)	42.2 (11.3)	<0.001
Female sex		546 (94.3%)	275 (96.2%)	0.243	487 (93.8%)	277 (92.3%)	0.408
		Ethnicity					
Asian		226 (39.0%)	101 (35.3%)	0.289	17 (3.3%)	9 (3.0%)	0.828
Black/African American		20 (3.5%)	10 (3.5%)	0.974	78 (15.0%)	38 (12.7%)	0.350
Indigenous American		189 (32.6%)	85 (29.7%)	0.385	65 (12.5%)	35 (11.7%)	0.718
White/Caucasian		139 (24.0%)	90 (31.5%)	0.019	352 (67.8%)	217 (72.3%)	0.177
		Clinical data					
SELENA-SLEDAI score		9.7 (3.6)	9.9 (4.1)	0.755	9.5 (9.0)	10.0 (3.8)	0.067
SLE disease duration (years)		5.1 (5.1)	5.8 (5.7)	0.130	7.2 (7.1)	8.1 (7.2)	0.045
SDI score		0.48 (0.90)	0.75 (1.15)	<0.001	0.92 (1.33)	1.13 (1.54)	0.054
SDI score = 0		400 (69.1%)	165 (57.7%)	0.001	273 (52.6%)	139 (46.5%)	0.092
Glucocorticoid use		555 (95.9%)	275 (96.2%)	0.834	374 (72.1%)	249 (83.0%)	<0.001
Prednisone dose (mg/day)		11.9 (8.5)	14.3 (9.0)	<0.001	8.1 (8.1)	10.0 (8.2)	<0.001
Immunosuppressants		219 (37.8%)	142 (49.7%)	0.001	257 (49.5%)	198 (66.0%)	<0.001
Azathioprine		134 (23.1%)	88 (30.8%)	0.016	87 (16.8%)	80 (26.7%)	0.001
Methotrexate		46 (7.9%)	33 (11.5%)	0.084	98 (18.9%)	54 (18.0%)	0.754
Mycophenolic acid		31 (5.4%)	21 (7.3%)	0.247	73 (14.1%)	64 (21.3%)	0.007

Data are presented as numbers (percentage) or means (standard deviation). Statistically significant *p*-values are indicated in bold. AMA: antimalarial agents; SELENA-SLEDAI: Safety of Estrogens in Lupus National Assessment Systemic Lupus Erythematosus Disease Activity Index; SDI: Systemic Lupus International Collaborating Clinics (SLICC)/American College of Rheumatology (ACR) Damage Index.